去泛素化酶在皮肤病的研究进展  

Deubiquitinating enzymes in dermatoses

作　　者：和义敏 冯爱平[1] 陈善娟[1] 

机构地区：[1]华中科技大学同济医学院附属协和医院皮肤科,武汉430022

出　　处：《国际皮肤性病学杂志》2013年第6期380-383,共4页International Journal of Dermatology and Venereology

基　　金：国家自然科学基金（81101191）

摘　　要：去泛素化酶家族种类繁多，分布于人体多种器官及组织，是泛素-蛋白酶体途径的重要组成部分，精细调控真核细胞生物细胞内蛋白的降解。A20、CYLD、泛素特异性加工酶7等去泛素化酶通过与外异蛋白受体、Fas相关的死亡区蛋白、B细胞淋巴因子-3、核因子-KB抑制蛋白激酶等因子相互作用，可参与银屑病、皮肤基底细胞癌、皮肤鳞状细胞癌、皮肤附属器肿瘤、Kaposi肉瘤以及恶性黑素瘤等皮肤疾病的发生发展。探讨去泛素化酶作用机制，有助于为炎症及肿瘤性皮肤病提供新的治疗靶点。There are a great variety of deubiquitinating enzymes （DUBs） distributed in multiple human tis sues and organs. As an important part of ubiquitin-proteasome pathway （UPP）, DUBs can tightly control the degra dation of eukaryotic intracellular proteins. It has been revealed that some deubiquitinating enzymes such as A20, cylindromatosis （CYLD） and ubiquitin-speeific processing protease-7 （USP7） may take part in the occurrence and development of psoriasis, basal cell carcinoma, squamous cell carcinoma, cutaneous adnexal neoplasms, Kaposis sarcoma and malignant melanoma through interaction with ectodysplasin-A receptor （EDAR）, Fas-assoeiated death domain-containing protein （FADD）, B-cell leukemia/lymphoma 3 （Bcl-3）, I kappa B kinase （IKK）, and so on. Therefore, exploring the action mechanism of deubiquitinating enzymes will help to find new targets for the treat ment of inflammatory dermatoses and skin tumors.

关 键 词：皮肤疾病 泛素类 去泛素化酶 

分 类 号：R751[医药卫生—皮肤病学与性病学]